The first Singapore study of its kind to provide insights into heart disease, diabetes, cancer and other chronic diseases
ZURICH, Switzerland, Jan. 09, 2023 (GLOBE NEWSWIRE) — BC Platforms (BCP), the global leader in healthcare data management and analytics, today announced that it has been selected as the preferred platform for analyzing and managing data collected from the Singapore Health for Life Study (Helios). ), which forms part of the SG100K dataset of the National Precision Medicine Program in Singapore.
The HELIOS study is a recent cohort population study created and led by the Lee Kong Chian School of Medicine (LKCMedicine) at Nanyang Technological University, Singapore (NTU Singapore). The population study aims to identify the environmental, lifestyle and genetic factors that cause heart disease, diabetes, cancer and other chronic diseases in Singapore.
As part of the SG100K study in Singapore, the HELIOS study will recruit up to 50,000 men and women, ages 30 to 84, who are residents of Singapore progressively over the next two years. BCP BC | INSIGHT and BC | RQUEST to manage LKCMedicine genotype and patient phenotype data of a large Asian cohort in a safe and secure manner.
Making HELIOS-SG100K data accessible through BC platforms will enable and accelerate researchers to pursue key questions around precision health and personalized medicine.
Nino Da Silva, Deputy General Manager, BC Platforms, He said, “I am delighted that we have more good news coming out of Singapore, a key focus for deploying our clinical solutions and driving precision medicine, as we work with leading Asian healthcare organizations. This latest partnership should make it easier for health providers to identify optimal pathways to treat patients in Key disease regions, based on insights into population health using our genomic data management platform. The rich multi-ethnicity of Asia is invaluable for life sciences research and clinical decision-making.”
NTU LKCMedicine Professor John Chambers, SG100K Senior Investigator, He said, “The unique and comprehensive measurements and samples collected, together with long-term follow-up will enable the investigation of the complex interrelationships between environmental, lifestyle and genetic factors on subsequent disease risk. The HELIOS study will provide a powerful resource for medical research across a wide range of disciplines To both current and future generations of biomedical researchers, we are delighted to have chosen BC Platforms as a key delivery partner on this important healthcare project.”
“BC platforms provide an environment to bring researchers into the data, allowing them to analyze de-identified data in a safe and secure way,” he explained. NTU LKCMedicine Assistant Professor Mary Lou. “Creating this trusted research environment is a key step in enabling researchers to use the data to explore the pathways underlying health and disease in Singapore.”
BC Platforms is steadily strengthening its presence in Asia, as part of its mission to deliver industry-leading management and analytics capacity for genomics and clinical data in Asia and around the world. Singapore is the fastest growing market in Asia, with a strong government commitment to facilitating genomics-related research and innovation using genomic and clinical data. Asian real world data is underrepresented in global life sciences research. Through BCP’s collaborations in the region with national healthcare systems, the company enables researchers secure access to carefully curated, high-quality data from Asia, to help build new medical diagnoses and treatments.
The project will benefit from the latest BCP software solution called Trusted Collaboration Environment (TCE) and the latest update to version 7. of the open platform BC | Acclaimed INSIGHT. The platform places great emphasis on user experience, and is fully equipped with a suite. Build tools and capabilities to automate highly dynamic data release approval processes and open workspaces. TCE is built on the basis of a Trusted Research Environment (TRE), a secure computing environment that manages sensitive patient data while allowing researchers access to it. TCEs are increasingly vital tools in enabling international collaborative research because they enable multiple data partners to securely share real-world data (RWD).
Notes to editors
About BC pads
BC Platforms is a leading global builder of data networks for the life sciences industry and provides versatile technology platforms for personalized medicine, accelerating the translation of innovations into clinical practice. We transform complex biological information collected in the healthcare environment into actionable insights. Through our innovative technology, we are creating an endless, patient-centered loop between the life sciences and healthcare sectors. The data we generate, curate, and manage, from biobanks and diverse healthcare organizations, is available to pharmaceutical and biotechnology companies to advance their core strengths in research and development. In parallel, we are enabling patient stratification toward targeted therapies, delivering on the promise of more personalized healthcare.
Our high-performance genomic data discovery and analytics platform enables flexible data integration, secure analysis, and interpretation of molecular and clinical information. We have developed our global data partner network, BCRQUEST.com, which provides access to high-quality real-world data. This rapidly growing network has a footprint across many locations, including major hospital networks, covering 20 countries on five continents, and providing a standard of care data for more than 23 million patients. Our platforms facilitate access to highly enriched data for seamless pharmaceutical R&D.
Founded in 1997 from an offshoot of the MIT Whitehead Project, we have a strong scientific heritage backed by more than 25 years of working in close collaboration with a network of leading researchers, developers, and industry partners. We have global operations with our headquarters in Zurich, Switzerland, R&D in Espoo, Finland, and Singapore, in addition to our presence in London and Boston. For more information, visit our website website And we followed linkedin.
BC Platforms AG
Tel: +358 40590 5733
Tel: +44 7789435990
Tel: +44 7747875479